^
Association details:
| Biomarker: | PTEN deletion |
|---|---|
| Cancer: | Prostate Cancer |
| Drug: | Keytruda (pembrolizumab) (PD1 inhibitor) + GSK2636771 (PI3Kβ inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Phase I/II study of the selective PI3Kβ inhibitor GSK2636771 in combination with pembrolizumab in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and PTEN loss.
Published date:
05/26/2022
Excerpt:
Among 11 evaluable pts at 200mg daily of GSK2636771, partial response (PR) was achieved in 2 pts (-56% and -59% as compared to baseline, per RECIST1.1), which was associated with ongoing progression free survival (PFS) > 12 months (24.1 and 13.6 months, respectively) and PSA > 50% reduction as compared to baseline. In addition, a pt with tumor reduction of 18% per RECIST1.1 has remained on treatment for 15.8 months...GSK2636771 plus pembrolizumab had an acceptable safety and tolerability profile. The combination showed promising preliminary antitumor activity and durable responses in a heavily pretreated population of pts with mCRPC.
DOI:
10.1200/JCO.2022.40.16_suppl.5052
Trial ID:
